Atea Pharmaceuticals, Inc.
AVIRNasdaq
$4.87
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↑ +39.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$385.7M
Enterprise Value
$129.7M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$169.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-72.4%
ROIC
—
Debt / Equity
—
Net Cash
$256.0M
Return 1Y
+40.8%
Company profile
Atea Pharmaceuticals, Inc. focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor, and AT-281, a pharmaceutically acceptable salt.
- CEO
- Jean-Pierre Sommadossi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Massachusetts
- Website
- ateapharma.com
Management & directors
- Corcoran AndreaSee Remarks
- Sommadossi Jean-PierrePresident, CEO, and Chairman
- Foster WayneEVP, Chief Accounting Officer
- Hammond Janet MjChief Development Officer
- Horga Maria ArantxaChief Medical Officer
- Vavricka JohnChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
AVIR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.57↑ +42.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $48.6M | $351.4M | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$11.0M | $138.4M | -$130.7M | -$164.2M | -$192.9M | -$180.9M |
| Net income | -$10.9M | $121.0M | -$116.0M | -$136.0M | -$168.0M | -$158.0M |
| Diluted EPS | -$0.51 | $1.37 | -$1.39 | -$1.63 | -$2.00 | -$1.94 |
| Operating cash flow | $296.7M | -$87.0M | -$121.0M | -$85.4M | -$135.5M | -$132.0M |
| Free cash flow | $296.7M | -$87.0M | -$122.9M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -22.7% | 39.4% | — | — | — | — |
| Net margin | -22.5% | 34.4% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$46.9M | -$37.2M | -$39.0M | -$39.0M | -$41.3M | -$45.6M | -$54.9M | -$48.0M |
| Net income | -$40.5M | -$31.2M | -$33.2M | -$34.3M | -$37.2M | -$42.0M | -$44.5M | -$45.4M |
| Diluted EPS | -$0.48 | -$0.37 | -$0.40 | -$0.40 | -$0.44 | -$0.53 | -$0.57 | -$0.57 |
| Operating cash flow | -$42.2M | -$23.0M | -$30.4M | -$30.6M | -$32.9M | -$40.4M | -$28.2M | -$46.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 18, 2026
Jun 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Polsky Bruce | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-06-18 | Lucidi Bruno | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-06-18 | Murphy Polly A. | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-06-18 | Duncan Barbara Gayle | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-06-18 | Adams Jerome M. | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-06-18 | BERGER FRANKLIN M | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2026-05-18 | Murphy Polly A. | Buy | 6,100 | $4.17 | $25,446.15 | filing |
| 2026-03-11 | Corcoran Andrea· See Remarks | Option exercise | 60,000 | $1.24 | $74,400.00 | filing |
| 2026-02-03 | Sommadossi Jean-Pierre· President, CEO, and Chairman | Option exercise | 300,000 | $1.24 | $372,000.00 | filing |
| 2026-01-31 | Sommadossi Jean-Pierre· President, CEO, and Chairman | Tax withholding | 106,093 | $4.24 | $449,834.32 | filing |
| 2026-01-31 | Corcoran Andrea· See Remarks | Tax withholding | 16,104 | $4.24 | $68,280.96 | filing |
| 2026-01-31 | Horga Maria Arantxa· Chief Medical Officer | Tax withholding | 16,073 | $4.24 | $68,149.52 | filing |
| 2026-01-31 | Hammond Janet MJ· Chief Development Officer | Tax withholding | 14,136 | $4.24 | $59,936.64 | filing |
| 2026-01-31 | Foster Wayne· EVP, Chief Accounting Officer | Tax withholding | 12,132 | $4.24 | $51,439.68 | filing |
| 2026-01-31 | Vavricka John· Chief Commercial Officer | Tax withholding | 11,570 | $4.24 | $49,056.80 | filing |
| 2026-01-31 | Hammond Janet MJ· Chief Development Officer | Option exercise | 58,050 | — | — | filing |
| 2026-01-31 | Horga Maria Arantxa· Chief Medical Officer | Option exercise | 51,283 | — | — | filing |
| 2026-01-31 | Vavricka John· Chief Commercial Officer | Option exercise | 42,083 | — | — | filing |
| 2026-01-31 | Corcoran Andrea· See Remarks | Option exercise | 54,866 | — | — | filing |
| 2026-01-31 | Sommadossi Jean-Pierre· President, CEO, and Chairman | Option exercise | 272,983 | — | — | filing |
| 2026-01-31 | Foster Wayne· EVP, Chief Accounting Officer | Option exercise | 41,333 | — | — | filing |
| 2025-06-20 | Murphy Polly A. | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2025-06-20 | BERGER FRANKLIN M | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2025-06-20 | Duncan Barbara Gayle | Option exercise | 29,600 | $0.00 | $0.00 | filing |
| 2025-06-20 | Polsky Bruce | Option exercise | 29,600 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.